Literature DB >> 10436291

Nicotine replacement therapy.

R V Fant1, L L Owen, J E Henningfield.   

Abstract

Physicians can help their patients quit smoking by recommending to all of their patients that they quit smoking with the help of nicotine replacement medications. Currently available forms of nicotine medications include gum, patch, nasal spray, and vapor inhaler. Nicotine replacement medications aid smokers in their cessation efforts by relieving the physiologic symptoms of nicotine withdrawal. Because nicotine medications do not deliver the myriad toxins and carcinogens cigarettes deliver, these medications are safe when used as directed. This article discusses the rationale behind nicotine replacement therapy in the context of tobacco dependence, the available medications, and the public health benefits of these medications.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10436291     DOI: 10.1016/s0095-4543(05)70121-4

Source DB:  PubMed          Journal:  Prim Care        ISSN: 0095-4543            Impact factor:   2.907


  13 in total

1.  Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving.

Authors:  Saul Shiffman; William G Shadel; Raymond Niaura; Moise A Khayrallah; Douglas E Jorenby; Charles F Ryan; Clifford L Ferguson
Journal:  Psychopharmacology (Berl)       Date:  2003-02-25       Impact factor: 4.530

2.  Abstinence from smoking reduces incisional wound infection: a randomized controlled trial.

Authors:  Lars Tue Sorensen; Tonny Karlsmark; Finn Gottrup
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

3.  Early nicotine withdrawal and transdermal nicotine effects on neurocognitive performance in schizophrenia.

Authors:  Christopher G AhnAllen; Paul G Nestor; Martha E Shenton; Robert W McCarley; Margaret A Niznikiewicz
Journal:  Schizophr Res       Date:  2007-09-19       Impact factor: 4.939

Review 4.  Measures for assessing subjective effects of potential reduced-exposure products.

Authors:  Karen Hanson; Richard O'Connor; Dorothy Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

5.  Separate and combined effects of the cannabinoid agonists nabilone and Δ⁹-THC in humans discriminating Δ⁹-THC.

Authors:  Joshua A Lile; Thomas H Kelly; Lon R Hays
Journal:  Drug Alcohol Depend       Date:  2011-01-11       Impact factor: 4.492

6.  Effects of transdermal nicotine and concurrent smoking on cognitive performance in tobacco-abstinent smokers.

Authors:  Bethea A Kleykamp; Janine M Jennings; Thomas Eissenberg
Journal:  Exp Clin Psychopharmacol       Date:  2011-02       Impact factor: 3.157

7.  Timing of nicotine lozenge administration to minimize trigger induced craving and withdrawal symptoms.

Authors:  Michael Kotlyar; Bruce R Lindgren; John P Vuchetich; Chap Le; Anne M Mills; Elizabeth Amiot; Dorothy K Hatsukami
Journal:  Addict Behav       Date:  2017-02-10       Impact factor: 3.913

Review 8.  The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments.

Authors:  N G Schneider; R E Olmstead; M A Franzon; E Lunell
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 9.  Clinical trials methods for evaluation of potential reduced exposure products.

Authors:  Dorothy K Hatsukami; Karen Hanson; Anna Briggs; Mark Parascandola; Jeanine M Genkinger; Richard O'Connor; Peter G Shields
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 10.  Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status.

Authors:  August R Buchhalter; Reginald V Fant; Jack E Henningfield
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.